After releasing downright worrisome first-quarter results, Gilead Sciences (NASDAQ: GILD) has seen its shares drop by a noteworthy 11.7% in the past few days. The big concern is that Gilead's ailing hepatitis C franchise has yet to stabilize …
It appeared that Gilead Sciences, Inc. (NASDAQ:GILD) had turned the corner earlier this year after a long slump. Just three years ago, Gilead reached a high of $120 per share at the height of its HCV treatment sales surge. Then its revenues …
SmarTrend identified an Uptrend for Exact Sciences (NASDAQ:EXAS) on April 12th, 2018 at $44.25. In approximately 1 month, Exact Sciences has returned 14.73% as of today's recent price of $50.77. Exact Sciences share prices have …
April 25 (Reuters) - Jubilant Life Sciences Ltd: * CO, JUBILANT STOCK HOLDING, OTHERS FILED APPEALS …
The S&P/TSX Composite Index progressed 39.11 points, or 0.25%, to close Friday's trading session at 15,577.81. The …
In May, Andrew Left of Citron Research blasted Exact Sciences (NASDAQ: EXAS), calling the stock "a poster child for what goes wrong when Wall Street gets a hold of a healthcare concept with no discrimination for whether it's good or …
Owning a stock that doubles in value in less than 11 months is exciting. But what word do you use for a stock that rises to 4.5 times its original price in that amount of time? Thrilling? Exhilarating? Whatever word is the best fit, it applies to …
With nothing more than a quick view of its chart and a passing glance at the headlines, it would be easy to decide Gilead Sciences, Inc. (NASDAQ:GILD) is best left avoided. The GILD stock price took a fairly big tumble after the release of its …
Every day, Wall Street analysts upgrade some stocks, downgrade others, and "initiate coverage" on a few more. But do these analysts even know what they're talking about? Today, we're taking one high-profile Wall Street pick and putting it …